Changes in Beneficial Ownership · 4
CERo Therapeutics Holdings, Inc.
Changes in Beneficial Ownership
Structured filing — 4
ownership.xml
Filing details
- Report period
- 2026-01-07
- Issuer
- CERO THERAPEUTICS HOLDINGS, INC.
- Issuer CIK
- 0001870404
- Trading symbol
- CERO
Reporting owner 1
- Name
- ATWOOD BRIAN G
- Reporting owner CIK
- 0001266567
- Relationship
- Director
- Address
- CERO THERAPEUTICS HOLDINGS, INC., 201 HASKINS WAY, SUITE 230, SOUTH SAN FRANCISCO, CA, 94080
Derivative transactions
| Security | Conversion / exercise price (USD) | Transaction date | Code | Amount | A / D | Price (USD) | Exercisable | Expires | Underlying security | Underlying shares | Owned after | Ownership |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy) | 0.055 | 2026-01-07 | A · Form 4 | 1,612,099 | A | 0.00 | 2026-01-07 | 2036-01-06 | Common Stock | 1,612,099 | 1,612,099 | D |
Table key
- A · Form 4
- Acquisition by grant, award or otherwise under Rule 16b-3(d)
- A
- Acquired
- D
- Direct
Signature 1
- Signed
- /s/ Andrew Kucharchuk, Attorney-in-Fact
- Date
- 2026-01-09
Company context
CERo is an innovative immunotherapy company advancing the development of next generation engineered T cell therapeutics for the treatment of cancer. Its proprietary approach to T cell engineering integrates key functional attributes of both innate and adaptive immunity within a single therapeutic construct, designed to engage the body’s immune repertoire for more comprehensive tumor targeting. This novel cellular immunotherapy platform is designed to redirect patient-derived T cells toward tumor cells through both adaptive perforin/granzyme pathways and innate engulfment mechanisms, including targeting of the TIM-4 ligand. This employs phagocytic activity to destroy cancer cells, creating what CERo refers to as Chimeric Engulfment Receptor T cells (“CER-T”). CERo believes the differentiated targeting properties of CER-T cells may offer advantages compared with currently approved CAR-T therapies and could potentially extend the reach of cellular immunotherapy to both hematologic malignancies and solid tumors. CERo has initiated clinical trials for its lead product candidate, CER-1236, for hematologic malignancies.
Current securities
Historical securities (7)
Recent company filings
- 10-Q filingNov 13, 2026
- Entry into a Material Definitive AgreementOct 7, 2026
- Entry into a Material Definitive Agreement · Termination of a Material Definitive Agreement · Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement · Unregistered Sales of Equity SecuritiesAug 31, 2026
- 424B3 filingAug 14, 2026
- 10-Q filingAug 14, 2026